فالنتينا أمبروزيني
Ambrosini, Valentina
VIAF ID: 5943147270518435700003 ( Personal )
Permalink: http://viaf.org/viaf/5943147270518435700003
Preferred Forms
-
100 1 _ ‡a Ambrosini, Valentina
-
-
-
100 0 _ ‡a فالنتينا أمبروزيني
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. |
![]() |
18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. |
![]() |
18F-FDG PET/CT detects systemic involvement in sarcoidosis |
![]() |
¹⁸F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. |
![]() |
18F-FDG PET/CT impact on testicular tumours clinical management. |
![]() |
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma |
![]() |
68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. |
![]() |
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. |
![]() |
68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. |
![]() |
68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. |
![]() |
68Ga DOTANOC PET/CT detects primary malignant insulinoma. |
![]() |
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. |
![]() |
The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. |
![]() |
Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. |
![]() |
Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. |
![]() |
Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). |
![]() |
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma |
![]() |
The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? |
![]() |
Detection of unknown primary neuroendocrine tumours |
![]() |
Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. |
![]() |
Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients |
![]() |
Dual PET/CT with |
![]() |
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. |
![]() |
Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism. |
![]() |
FDG PET/CT in autoimmune pancreatitis |
![]() |
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. |
![]() |
FDG small animal PET permits early detection of malignant cells in a xenograft murine model. |
![]() |
Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. |
![]() |
Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT |
![]() |
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? |
![]() |
Is there an ideal diagnostic algorithm in solitary pulmonary nodules? |
![]() |
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. |
![]() |
Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. |
![]() |
Molecular imaging of pulmonary nodules. |
![]() |
A new dimension of FDG-PET interpretation: assessment of tumor biology. |
![]() |
Performance evaluation of a small animal PET scanner. Spatial resolution characterization using 18F and 11C |
![]() |
PET/CT imaging in different types of lung cancer: an overview. |
![]() |
PET/CT in neuroendocrine tumors, 2016: |
![]() ![]() ![]() |
PET/CT with 68Gallium-DOTA-peptides in NET: an overview. |
![]() |
Positron-emission tomography in gynaecologic malignancies. |
![]() |
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. |
![]() |
Radiopeptide imaging and therapy in Europe. |
![]() |
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. |
![]() |
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. |
![]() |
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. |
![]() |
Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. |
![]() |
Small animal PET for the evaluation of an animal model of genital infection. |
![]() |
Small animal PET in oncology: the road from bench to bedside. |
![]() |
Standardized uptake values of |
![]() |
The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. |
![]() |
The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. |
![]() |
Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. |
![]() |